XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Equity Incentive Plans (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Schedule of Share-based Compensation Costs

The following is a summary of such share-based compensation costs included in the Company’s consolidated statements of operations for the years ended December 31, 2023 and 2022:

 

   2023   2022 
   For the Twelve Months Ended December 31, 
   2023   2022 
Share-based compensation expense included in:          
Cost of revenue  $4,898   $12,403 
Advertising and marketing expenses   1,113    13,921 
Product development costs   3,570    7,442 
Selling, general and administrative expenses   178,033    280,315 
Total share-based compensation expense included in consolidated statement of operations  $187,614   $314,081 
Schedule of Restricted Units Activity

A summary of the RSUs awarded to employees, directors and consultants under the 2021 Equity Plan during the years ended December 31, 2023 and 2022 are presented in the table below:

 

  Number of
Units		   Weighted Average Grant-Date
Fair Value		   Aggregate
Intrinsic Value		 
            
Outstanding, December 31, 2021   -   $-   $- 
Granted   6,734   $7.42   $- 
Vested and settled with share issuance   (3,367)  $7.42   $- 
Forfeited/canceled   -   $-   $      - 
Outstanding, December 31, 2022   3,366   $7.42   $- 
Granted   119,032   $0.84   $- 
Vested and settled with share issuance   (122,398)  $1.02   $- 
Forfeited/canceled   -   $-   $- 
Outstanding, December 31, 2023   -   $-   $- 
2017 and 2021 Equity Plan [Member] | Employees and Consultants [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Schedule of Stock Option Activity

A summary of the stock options granted to employees and consultants under the 2017 Equity Plan and the 2021 Equity Incentive Plan during the years ended December 31, 2023 and 2022 are presented in the table below:

 

   Number of
Options		   Weighted Average
Exercise Price		   Weighted Average Remaining Contractual Term   Aggregate
Intrinsic Value		 
                 
Outstanding, December 31, 2021   158,174   $10.99    7.6   $- 
Granted   53,960   $2.90    9.2   $- 
Exercised   -   $-    -   $       - 
Forfeited   (20,061)  $8.85    8.6   $- 
Expired   -   $-    -   $- 
Outstanding, December 31, 2022   192,073   $8.94    7.6   $- 
Granted   138,489   $0.90    6.9   $- 
Exercised   -   $-    -   $- 
Forfeited   (20,296)  $2.98    9.1   $- 
Expired   (8,244)  $0.89    -   $- 
Outstanding, December 31, 2023   302,022   $5.87    6.6   $- 
Exercisable, December 31, 2023   292,022   $5.99    6.5   $- 
Summary of Non-vested Non-qualified Stock Option Activity

A summary of non-vested stock options activity for employees and consultants under the 2017 Equity Plan and the 2021 Equity Plan for the years ended December 31, 2023 and 2022 are presented in the table below:

 

  Number of
Options		   Weighted Average Grant-Date
Fair Value		   Aggregate
Intrinsic Value		   Grant-Date
Fair Value		 
                
Nonvested, December 31, 2021   41,846   $7.65   $-   $320,122 
Granted   53,960   $2.86   $-   $154,555 
Vested   (52,049)  $3.89   $-   $- 
Forfeited   (15,000)  $8.52   $     -   $- 
Expired   -   $-   $-   $- 
Nonvested, December 31, 2022   28,756   $5.03   $-   $144,541 
Granted   138,489   $0.88   $-   $122,344 
Vested   (156,912)  $0.92   $-   $(241,247)
Forfeited   (333)  $6.67   $-   $(2,225)
Expired   -   $-   $-   $- 
Nonvested, December 31, 2023   10,000   $2.18   $-   $22,000 
2017 and 2021 Equity Plan [Member] | Directors [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Schedule of Stock Option Activity

A summary of the non-qualified stock options granted to directors under the 2017 Equity Plan and 2021 Equity Plan during the years ended December 31, 2023 and 2022 are presented in the table below:

 

   Number of Options   Weighted Average Exercise Price   Weighted Average Remaining Contractual Term   Aggregate Intrinsic Value ($000) 
                 
Outstanding, December 31, 2021   50,872   $10.02    6.6   $- 
Granted   6,250   $4.80    9.0   $- 
Exercised   -    -    -   $- 
Forfeited/Cancelled   -    -    -   $- 
Expired   -    -    -   $- 
Outstanding, December 31, 2022   57,122   $9.44    6.0   $- 
Granted   -    -    -   $     - 
Exercised   -    -    -   $- 
Forfeited/Cancelled   -    -    -   $- 
Expired   -    -    -   $- 
Outstanding, December 31, 2023   57,122   $9.44    5.0   $- 
Exercisable, December 31, 2023   57,122   $9.44    5.0   $- 
Summary of Non-vested Non-qualified Stock Option Activity

A summary of non-vested non-qualified stock options activity for directors under the 2017 Equity Plan and the 2021 Equity Plan for the years ended December 31, 2023 and 2022 are presented in the table below:

 

  Number of
Options		   Weighted Average Grant-Date
Fair Value		   Aggregate
Intrinsic Value		   Grant-Date
Fair Value		 
                
Nonvested, December 31, 2021   -    -   $-   $- 
Granted   6,250   $4.75   $-   $29,656 
Vested   (6,250)  $4.75   $-   $- 
Forfeited   -    -   $       -   $- 
Expired   -    -   $-   $- 
Nonvested, December 31, 2022   -    -   $-   $- 
Granted   -    -   $-   $- 
Vested   -    -   $-   $- 
Forfeited   -    -   $-   $- 
Expired   -    -   $-   $- 
Nonvested, December 31, 2023   -        $-   $-